Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) – Pipeline Review, H2 2017’, provides in depth analysis on Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Infectious Disease, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology under development targeting Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects

The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aprea AB

CanBas Co Ltd

Critical Outcome Technologies Inc

Innovation Pharmaceuticals Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Quark Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development

Aprea AB

CanBas Co Ltd

Critical Outcome Technologies Inc

Innovation Pharmaceuticals Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Quark Pharmaceuticals Inc

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles

APR-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATRN-502 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

contusugene ladenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-12PGJ3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kevetrin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MHY-449 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MJ-05 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MX-225 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oncolytic Viruses to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OSE-2101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPAL-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGT-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Cdk2, Cdk4, Cdk6, Cyclin D1, Cyclin B1, Cdc2, p53 and p16 for Bacterial Infections and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Skin Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZMC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones

Featured News & Press Releases

Oct 16, 2017: Karolinska Developments portfolio company Aprea announces first patient enrolled in clinical phase 1b/2 study with APR-246 for the treatment of esophageal cancer

Oct 11, 2017: Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma

Sep 14, 2017: Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial

Sep 11, 2017: Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017

Aug 30, 2017: Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress

Aug 14, 2017: Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies

Aug 02, 2017: Karolinska Development company Aprea Therapeutics announces First Patient Enrolled in Phase Ib/II Clinical Study

Jul 27, 2017: Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery

Jun 23, 2017: OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi in Advanced Lung Cancer

May 30, 2017: Cellceutix Anti-Cancer Drug Candidates p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the 2017 European Hematology Association Annual Meeting

May 23, 2017: Aprea Therapeutics Announces First Patients Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Myelodysplastic Syndrome

Apr 03, 2017: Cellceutix AACR Poster Presents Data Supporting Kevetrin Modulation of p53 in Multiple Human Ovarian Cancer Cell-lines and Corresponding Xenograft Tumors

Mar 03, 2017: Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Oral Anti-Cancer Agent

Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801

Feb 10, 2017: Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p53 Drug Candidate Kevetrin in the Treatment of Platinum-Resistant/Refractory Ovarian Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Aprea AB, H2 2017

Pipeline by CanBas Co Ltd, H2 2017

Pipeline by Critical Outcome Technologies Inc, H2 2017

Pipeline by Innovation Pharmaceuticals Inc, H2 2017

Pipeline by ORCA Therapeutics BV, H2 2017

Pipeline by OSE Immunotherapeutics, H2 2017

Pipeline by Quark Pharmaceuticals Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Dormant Products, H2 2017 (Contd..3), H2 2017

Dormant Products, H2 2017 (Contd..4), H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports